Krystal Biotech, Inc.

NASDAQ (USD): Krystal Biotech, Inc. (KRYS)

Last Price

213.66

Today's Change

+2.97 (1.40%)

Day's Change

211.00 - 219.34

Trading Volume

222,619

Overview

Market Cap

6 Billion

Shares Outstanding

28 Million

Avg Volume

404,759

Avg Price (50 Days)

180.00

Avg Price (200 Days)

145.17

PE Ratio

98.46

EPS

2.17

Earnings Announcement

05-Aug-2024

Previous Close

210.69

Open

213.24

Day's Range

211.005 - 219.34

Year Range

93.95 - 219.34

Trading Volume

222,619

Price Change Highlight

1 Day Change

1.41%

5 Day Change

4.52%

1 Month Change

16.84%

3 Month Change

36.19%

6 Month Change

84.14%

Ytd Change

70.98%

1 Year Change

76.20%

3 Year Change

274.84%

5 Year Change

328.69%

10 Year Change

1908.08%

Max Change

1908.08%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment